• Conformational changes in ADAMTS-13 are part of its mode-of-action.
Summary. Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is an autoimmune disorder characterized by absent ADAMTS-13 activity and the presence of anti-ADAMTS-13 autoantibodies. Recently, it was shown that ADAMTS-13 adopts a folded or an open conformation. Objectives: As conformational changes in self-antigens play a role in the pathophysiology of different autoimmune diseases, we hypothesized that the conformation of ADAMTS-13 changes during acute aTTP. Methods: Antibodies recognizing cryptic epitopes in the spacer domain were generated. Next, the conformation of ADAMTS-13 in 40 healthy donors (HDs), 99 aTTP patients (63 in the acute phase versus 36 in remission), 12 hemolytic-uremic syndrome (HUS) patients and 63 sepsis patients was determined with ELISA. Results: The antibody 1C4 recognizes a cryptic epitope in ADAMTS-13. Therefore, we were able to discriminate between a folded and an open ADAMTS-13 conformation. We showed that ADAMTS-13 in HDs does not bind to 1C4, indicating that ADAMTS-13 circulates in a folded conformation. Similar results were obtained for HUS and sepsis patients. In contrast, ADAMTS-13 of acute aTTP patients bound to 1C4 in 92% of the cases, whereas, in most cases, this binding was abolished during remission, showing that the conformation of ADAMTS-13 is open during an acute aTTP episode. Conclusions: Our study shows that, besides absent ADAMTS-13 activity and the presence of anti-ADAMTS- 13 autoantibodies, an open ADAMTS-13 conformation is also a hallmark of acute
Introduction
Deficiency of ADAMTS-13 leads to the rare and lifethreatening disease thrombotic thrombocytopenic purpura (TTP). TTP is caused by mutations in the ADAMTS13 gene (congenital) or by the development of anti-ADAMTS-13 autoantibodies (acquired TTP [aTTP]) [1, 2] . ADAMTS-13 consists of 14 domains: a metalloprotease (M), a disintegrin-like (D), a thrombospondin type-1 repeat (T), a cysteine-rich (C), a spacer (S), seven additional T, and two CUB domains [3] . The multimeric size of von Willebrand factor (VWF) is regulated by ADAMTS-13. Shear stress induces conformational changes in the VWF A2 domain, which results in exposure of the ADAMTS-13 cleavage site and subsequent VWF proteolysis (reviewed by Crawley et al. [4] ). Recently, it was shown that VWF allosterically activates ADAMTS-13. Indeed, ADAMTS-13 adopts a folded conformation by a spacer-CUB domain interaction [5] . This spacer-CUB autoinhibition is relieved by interaction of ADAMTS-13 with its substrate VWF, or can be induced in vitro by the addition of activating anti-CUB antibodies [5] [6] [7] . Although a conformational change in ADAMTS-13 is part of its mode-of-action, it remains unknown whether conformational changes in ADAMTS-13 play a role in the pathophysiology of aTTP. In autoimmune diseases such as antiphospholipid syndrome (APS) and heparininduced thrombocytopenia (HIT), conformational changes in the self-antigens b 2 -glycoprotein I (b 2 GPI) and platelet factor 4 (PF4), respectively, result in exposure of cryptic epitopes and subsequent binding of anti-b 2 GPI and anti-PF4 autoantibodies to the self-antigens in these patients [8, 9] . Therefore, in this study, we investigated whether exposure of cryptic epitopes in ADAMTS-13 play a role in the pathophysiology of aTTP. mAbs that recognize cryptic epitopes in the spacer domain of ADAMTS-13 were developed, to enable discrimination between folded and open ADAMTS-13. We next showed that cryptic epitopes are exposed in ADAMTS-13 during acute aTTP, but not in aTTP patients in remission, healthy donors (HDs), hemolytic-uremic syndrome (HUS) patients, or sepsis patients. Hence, exposure of cryptic epitopes in ADAMTS-13 is a specific feature of acute aTTP.
Materials, patients, and methods

Mouse anti-human ADAMTS-13 antibodies
Mouse anti-human ADAMTS-13 antibodies 3H9 and 17G2 are in-house-developed antibodies directed against the metalloprotease and CUB1 domains of ADAMTS-13, respectively [7, 10] . Antibody 3H9 is a potent inhibitor of ADAMTS-13 [10] , whereas 17G2 induces a more open ADAMTS-13 conformation [5] [6] [7] .
The anti-spacer domain antibodies II-1 and I-9 are two antibodies isolated from aTTP patients. They both recognize the residues R568, R660, Y661, and Y665, and II-1 also targets F592 [11, 12] .
Expression and purification of recombinant human ADAMTS-13 (rhADAMTS-13) and recombinant human MDTCS (rhMDTCS) rhADAMTS-13 and rhMDTCS with a C-terminal His-tag and V5-tag were produced as previously described [13, 14] . Conditioned medium was ultrafiltrated and dialyzed against the appropriate binding buffer (20 mM imidazole, 20 mM NaH 2 PO 4 .H 2 O, 500 mM NaCl, pH 7.4) with a 4MA ultrafiltration hollow-fiber cartridge (GE Healthcare, Waukesha, WI, USA). Next, the dialyzed medium was loaded onto a Zn 2+ -coupled HisTrap HP column coupled to an € AKTA (GE Healthcare). Fractions were eluted with an imidazolecontaining buffer (500 mM imidazole, 20 mM NaH 2-PO 4 .H 2 O, 500 mM NaCl, pH 7.4). Positive fractions were pooled and dialyzed against HEPES-buffered saline (50 mM HEPES, 5 mM CaCl 2 .2H 2 O, 1 lM ZnCl 2 , 150 mM NaCl).
Generation of anti-rhMDTCS antibodies
Mouse anti-rhMDTCS mAbs were developed as previously described [7, 15, 16] . The supernatant of the hybridoma cells was transferred to 96-well microtiter plates coated with rhMDTCS (2 lg mL
À1
), for selection of positive clones. Bound antibodies were detected with horseradish peroxidase (HRP)-labeled goat anti-mouse antibody (GAM-HRP) (1 : 10 000; Jackson Immunoresearch, Newmarket, UK). Colorimetric development was performed with o-phenylenediamine and H 2 O 2 . The reaction was stopped with 4 M H 2 SO 4 , and absorbance was measured at 490 nm. Antibodies were produced and purified as previously described [7] .
Epitope mapping
Epitope mapping of anti-rhMDTCS antibodies was performed with M, MD, MDT and MDTCS variants containing FLAG tags [17] , as previously described [7] .
Fine mapping of the epitope of 1C4 was performed via immunoprecipitation with previously described MDTCS variants in which specific amino acids in the spacer domain were mutated to an alanine (MDTCS-R568A, MDTCS-F592A, MDTCS-R568A/F592A, MDTCS-R660A/Y661A/ Y665A [MDTCS-RYY], MDTCS-RYY-R568A, MDTCS-RYY-F592A, and MDTCS-RYY-R568A/F592A) [11, 12] . All mutants were incubated with either 1C4 or I-9 and II-1 [11, 12] , all bound to protein G Sepharose (GE Healthcare). Anti-V5 antibody (Invitrogen, Carlsbad, CA, USA) was used as a positive control. The results were analyzed with SDS-PAGE and western blotting as described elsewhere [11] .
Identifying anti-MDTCS antibodies recognizing a cryptic epitope in ADAMTS-13 (5 lg mL À1 ) were coated on a microtiter plate. Next, rhADAMTS-13 or rhMDTCS (5.7 nM) were added and further diluted 1 : 2. Bound rhADAMTS-13 or rhMDTCS was detected with HRP-labeled anti-V5 antibodies (1 : 3000). Colorimetric development was performed as described above.
Binding of anti-rhMDTCS antibodies to coated rhADAMTS-13. Microtiter plates were coated with rhADAMTS13 (15 nM). The anti-rhMDTCS antibodies 3H9 and 1C4 (5 lg mL À1 ) were added and further diluted 1 : 2. Bound antibodies were detected with GAM-HRP (1 : 10 000). Colorimetric development was performed as described above.
Inducing an open conformation of rhADAMTS-13 with 17G2. A preblocked plate was used to preincubate rh-ADAMTS-13 (starting concentration of 0.5 lg mL À1 ) diluted 1 : 2 with constant amounts of the activating anti-CUB1 antibody 17G2 [7] (2.5 lg mL À1 ). As a reference, rhADAMTS-13 (0.5 lg mL
À1
) in the absence of 17G2 was also preincubated. Next, the samples were transferred to plates coated with 3H9 or 1C4 (5 lg mL
). Captured rhADAMTS-13 was detected with HRP-labeled anti-V5 antibody. Colorimetric development was performed as described above.
Plasma samples from thrombotic microangiopathy (TMA) patients (TTP and HUS)
For all tested subjects, venous blood was collected on 3.8% sodium citrate (1/10 of final volume); platelet-poor plasma was obtained as described previously [18] . Plasma samples from 40 HDs were available from KU Leuven, Belgium. HDs with known age and gender were included in the study (Table S1 ). Plasma samples from 81 idiopathic aTTP patients (81 acute aTTP and 36 matched aTTP remission samples) and 12 acute HUS patients were available from the French Reference Center for Thrombotic Microangiopathies (Lariboisi ere Hospital, Paris, France). Age, gender, ADAMTS-13 activity and ADAMTS-13 antibody titer were available for the 81 idiopathic aTTP patients in the acute and remission phases (Table S2) , and for the 12 HUS patients (Table S3 ). All 93 acute TMA patients (81 acute idiopathic aTTP, 36 matched remission aTTP and 12 acute HUS patients) were adults, and blood was collected before any treatment. The diagnosis of acute TMA was defined as previously described [18] . Acute aTTP was defined as a TMA linked to a severe ADAMTS-13 deficiency (activity measured with the FRETS-VWF73 assay of < 10%) [18] . Of 81 patients with acute idiopathic aTTP, 77 had a positive anti-ADAMTS-13 IgG antibody titer (> 15 IU mL
À1
, measured with the TECHNOZYME ADAMTS13-INH ELISA kit; Technoclone, Vienna, Austria), whereas four patients had an anti-ADAMTS-13
IgG antibody titer of ≤ 15 IU mL À1 (Table S2 ). All 81 aTTP patients recovered detectable ADAMTS-13 activity during remission, supporting the diagnosis of aTTP; remission samples were available in 36 of them (Table S2) . In all but two of the 36 remission samples, anti-ADAMTS-13 IgG antibody titers were undetectable (< 15 IU mL
). ADAMTS-13 activity was always > 10% in the 12 HUS patients (Table S3) . Plasma samples from 63 sepsis patients (Table S4 ) with known age and gender, and with Staphylococcus aureus bacteremia before treatment, were available from the biobank of UZ Leuven, Belgium [19] .
Informed consent was obtained from each patient according to the Declaration of Helsinki, and the study was approved by the Ethics Committee of the hospital UZ Leuven (NCT01911624; Leuven, Belgium) for HDs and sepsis patients, and by the Ethics Committee of Hospital Piti e-Salpêtri ere and Hospital Saint-Antoine (NCT00426686; Paris, France) for the idiopathic aTTP and HUS patients.
ADAMTS-13 antigen ELISA
ADAMTS-13 antigen levels were determined in all plasma samples as previously described [20] , with minor modifications. Plasma (1 : 12.5 or 1 : 25 starting dilution for patients and HDs, respectively) was added and further diluted 1.5 : 2.5. A normal human plasma (NHP) pool was used as a reference and set at 1 lg mL À1 . The detection limit of the ELISA is 0.02 lg mL À1 ADAMTS-13.
Identifying exposed cryptic epitopes in ADAMTS-13 of HDs and aTTP, HUS and sepsis patients (1C4 ELISA)
Plasma was diluted four times in the absence and presence of 17G2 (final concentration of 2.5 lg mL À1 ; to expose the cryptic epitope of 1C4) in a preblocked 96-well plate. As a reference curve and intra-assay control, a twofold dilution series of NHP (1 lg mL À1 ADAMTS-13)
was incubated with constant amounts of 17G2 (final concentration of 2.5 lg mL
À1
), resulting in a 0.5 lg mL
final starting concentration for ADAMTS-13. After preincubation, samples were transferred to 1C4 (5 lg mL À1 )-coated plates. Finally, bound ADAMTS-13 was detected with biotinylated 3H9, followed by HRP-labeled Pierce high-sensitivity streptavidin (1 : 10 000; Invitrogen). Colorimetric development was performed as described above.
Data were expressed as a conformation index. For calculation of the conformation index, the OD 490 nm values obtained after performance of the 1C4 ELISA were first corrected for ADAMTS-13 antigen concentrations, as binding of ADAMTS-13 to 1C4 is dependent on the amount of ADAMTS-13 present in the sample (see NHP reference curve, Fig. S1 ). Then, the antigen-corrected OD 490 nm values were normalized with the OD 490 nm of the intra-assay control (NHP [diluted 1 : 4] in the presence of 17G2, Fig. S1 ) to obtain a conformation index that is comparable between different plates.
Statistics GRAPHPAD PRISM v5.03 software (GraphPad Software, San Diego, CA, USA) was used for statistical analysis (one-way ANOVA, paired t-test) and correlations (Spearman correlation). A P-value of < 0.05 was considered to be statistically significant.
Results
The anti-ADAMTS-13 antibody 1C4 recognizes a cryptic epitope in rhADAMTS- 13 We first aimed at developing an antibody recognizing a cryptic epitope in the spacer domain, which should allow us to discriminate between folded and open ADAMTS-13. Hence, we immunized Balb/C mice with MDTCS. Ten novel anti-MDTCS mAbs were generated, and their epitopes were mapped by the use of MDTCS variants (M, MD, MDT, and MDTCS) [17] . Five antibodies had an epitope in the cysteine/spacer domain of ADAMTS-13 (data not shown). Of these five anti-cysteine/spacer domain antibodies, four recognized a surface and one a cryptic epitope in rhADAMTS-13. We show here the results for 1C4, which recognizes a cryptic epitope in ADAMTS-13, and, as a comparison, 15A6, which recognizes a surface epitope in the spacer domain of ADAMTS-13. First, 1C4 could efficiently capture MDTCS but not ADAMTS-13, showing that the epitope of 1C4 is cryptic when full-length ADAMTS-13 is in solution (Fig. 1A) . Full-length ADAMTS-13 mainly adopts a folded conformation in solution [6] , but a minority of the ADAMTS-13 molecules might be in an open conformation [21] . Hence, the residual binding of full-length ADAMTS-13 to 1C4 might be explained by the presence of some 'open' ADAMTS-13. In contrast, 15A6 captured MDTCS and ADAMTS-13 equally well (Fig. 1A) . As a reference, we used 3H9, the epitope of which in ADAMTS-13 is non-cryptic (Fig. 1A) [7, 10] . Second, as coating of proteins induces conformational changes [22] , subsequent binding of 1C4 to coated ADAMTS-13 ( Fig. 1B) suggests exposure of its cryptic epitope. As expected, 3H9 also bound to coated ADAMTS-13 ( Fig. 1B) [10] . Also, 1C4 could efficiently capture ADAMTS-13 ( Fig. 1C) when a conformational change in ADAMTS-13 was induced by our anti-CUB1 antibody 17G2 [5] [6] [7] , which is known to disrupt the spacer-CUB interaction [5, 6] . As expected, disrupting the spacer-CUB interaction with 17G2 did not alter the accessibility of the non-cryptic epitope of 3H9 (Fig. 1C) .
Finally, we fine-mapped the epitope of 1C4, located in the cysteine/spacer domain of ADAMTS-13, by using previously described MDTCS variants with alanine mutations in the spacer domain (MDTCS-R568A, MDTCS-F592A,  MDTCS-R568A/F592A,  MDTCS-RYY,  MDTCS-RYY-R568A,  MDTCS-RYY-F592A , and MDTCS-RYY-R568A/F592A) [11] . Binding of 1C4 to all mutants was abrogated, except for binding to MDTCS-F592A (Fig. 1D ). This indicates that 1C4 recognizes an epitope comprising R568, R660, Y661 and Y665 in the ADAMTS-13 spacer domain. This epitope is similar to the previously described epitope of I-9, and overlaps with the epitope of II-1, two anti-ADAMTS-13 autoantibodies isolated from aTTP patients [11, 12, 23] .
In conclusion, 1C4 recognizes an epitope in the spacer domain of ADAMTS-13 that is cryptic when ADAMTS-13 is in solution (Fig. 1E) . Disrupting the spacer-CUB interaction by coating ADAMTS-13 or by using the anti-CUB1 antibody 17G2 results in an open ADAMTS-13 conformation [7] , with the cryptic epitope of 1C4 exposed (Fig. 1E) . Hence, our findings show that 1C4 can discriminate between a folded and open ADAMTS-13 conformation.
ADAMTS-13 antigen levels in HDs, and aTTP, HUS and sepsis patients Next, we wanted to investigate the conformation of ADAMTS-13 in plasma of HDs and aTTP, HUS and sepsis patients by studying the binding of their ADAMTS-13 to 1C4 (1C4 ELISA). Obviously, only plasma samples with detectable ADAMTS-13 antigen levels could be used, which, especially in acute aTTP patients, might be an issue [18] . Therefore, ADAMTS-13 antigen levels in all plasma samples were first determined. As expected, all 40 HDs showed ADAMTS-13 levels within the normal range (1.14 AE 0.21 lg mL À1 ) ( Fig. 2 ; Table S1 ). In the group of acute aTTP patients, 67 of the 81 patients had detectable ADAMTS-13 levels (> 0.02 lg mL À1 ADAMTS-13) ( Fig. 2 ; Table S2 ). During remission, all patients had restored ADAMTS-13 levels (1.13 AE 0.41 lg mL À1 ) ( Fig. 2 ; Table S2 ). ADAMTS-13 was detectable in the 12 HUS patients (0.79 AE 0.44 lg mL À1 ) ( Fig. 2; Table S3 ) and in the 63 sepsis patients (0.56 AE 0.16 lg mL À1 ) ( Fig. 2 ; Table S4 ), as previously reported [24] . Hence, 67 of the 81 samples of acute aTTP patients and all samples of the HDs, aTTP patients in remission and HUS and sepsis patients could be used for further analyses.
A conformation index of > 0.5 is defined as open ADAMTS-13
We next studied the binding of ADAMTS-13 in plasma of HDs (n = 40) in the absence or presence of the anti-CUB1 antibody 17G2, and calculated the corresponding conformation index. When ADAMTS-13 in plasma of HDs was incubated with 17G2, an open conformation was induced, and ADAMTS-13 was captured by 1C4 (Fig. 3) . The conformation index from this open ADAMTS-13 varied from 0.5 to 1.8 (Fig. 3) . When ADAMTS-13 in plasma of HDs was not incubated with 17G2, the conformation remained folded, and the conformation index varied from 0.05 to 0.23 (Fig. 3) . Our data show that the cryptic epitope of 1C4 is definitely exposed (because 17G2 is added), and hence ADAMTS-13 is S  T2  T3  T4   T5  T6  T7  T8   CUB2 CUB1  M   D   T1  C   S  T2  T3  T4   T5  T6  T7  T8   CUB2CUB1   M   D   T1  C   S  T2  T3  T4   T5  T6  T7  T8   17G2 
ADAMTS-13 adopts an open conformation in aTTP patients during the acute phase
We next investigated whether the cryptic epitope of 1C4 is exposed, and hence the conformation of ADAMTS-13 is changed, in aTTP patients during the acute phase, as exposure of cryptic epitopes in self-antigens has been reported in other autoimmune disorders, such as HIT and APS [8, 25] . The conformation index of ADAMTS-13 in the 67 samples with detectable ADAMTS-13 antigen ( Fig. 2 ; Table S2 ) was determined in the 1C4 ELISA. In four plasma samples, the conformation index could not be calculated, because OD values were below the values of the linear part of the reference curve (Fig. S1 ). Interestingly, ADAMTS-13 adopts an open conformation in most acute aTTP patients (Fig. 4A) , in contrast to HDs (Fig. 3) . Indeed, 92% (58/63) of the acute aTTP patients had ADAMTS-13 in an open conformation, as ADAMTS-13 was captured by 1C4 ( Fig. 4A ; Table S2 ). Addition of 17G2 to this open conformation of ADAMTS-13 resulted in additional conformational changes in ADAMTS-13 in some of the patients ( Fig. 4B ; Table S2 ). In only five patients (TTP 004, TTP 005, TTP 048, TTP 055, and TTP 089), a folded conformation of ADAMTS-13 was observed ( Fig. 4A ; Table S2 ). Interestingly, in these patients, relatively high antigen levels were present (Table S2 ). In general, we found a negative correlation (Spearman correlation, r = À 0.3535) between ADAMTS-13 antigen levels and the conformation index (Fig. S2) . As in the HDs, these folded ADAMTS-13 conformations could be opened by 17G2 (except for TTP 055) (Table S2) . To investigate whether the open conformation of ADAMTS-13 is specific for the acute phase of aTTP, we analyzed 36 matched aTTP remission samples. In the majority of the aTTP patients in remission (28/36, 78%), ADAMTS-13 adopted a folded conformation, as ADAMTS-13 was not captured by 1C4 ( Fig. 4A ; Table S2 ). As we studied matched samples, we show here that, in 25 patients (three of 28 patients (TTP 004, TTP 048, and TTP 089) showed a folded conformation in the acute phase), ADAMTS-13 is open during the acute phase and folded during remission. Interestingly, in eight of the 36 aTTP patients in remission (TTP 020, TTP 040, TTP 042, TTP 047, TTP 058, TTP 061, TTP 094, and Fig. 2 . ADAMTS-13 antigen levels in healthy donors (HDs), acquired thrombotic thrombocytopenic purpura (aTTP) patients during the acute phase and during remission, hemolytic-uremic syndrome (HUS) patients, and sepsis patients. Plasma was added to the anti-ADAMTS-13-coated antibody 3H9 (5 lg mL
À1
). Bound ADAMTS-13 was detected with biotinylated anti-ADAMTS-13 antibodies 19H4 and 17G2, and horseradish peroxidase-labeled streptavidin. Normal human plasma was used as a reference, and set as 1 lg mL
. Sample numbers: HDs, n = 40; aTTP patients during the acute phase, n = 81; aTTP patients during remission, n = 36; sepsis patients, n = 63; and HUS patients, n = 12. TTP 098), an open conformation of ADAMTS-13 was still detected (Fig. 4A) . However, these conformation indices were lower than in their corresponding acute phase, indicating that these patients also had a larger proportion of closed ADAMTS-13 during remission ( Fig. 4C ; Table S2 ). As expected, the ADAMTS-13 conformation in remission (closed in 28 patients and open in eight patients) could be changed by 17G2 (Fig. S3) , just as in HDs (Fig. 3 ).
In conclusion, an open ADAMTS-13 conformation is specific for the majority of acute aTTP patients.
An open ADAMTS-13 conformation is specific for aTTP
To show that an open ADAMTS-13 conformation is specific for acute aTTP and not for other TMAs, we analyzed the plasma of 12 acute HUS patients. ADAMTS-13 in HUS patients was not captured by 1C4, suggesting a (A) Plasma samples of acute aTTP (n = 63) patients, aTTP patients in remission (n = 36), sepsis (n = 63) patients and hemolytic-uremic syndrome (HUS) (n = 12) patients were added to wells coated with the anti-ADAMTS-13 antibody 1C4 (recognizing a cryptic epitope in ADAMTS-13), and captured ADAMTS-13 was detected with biotinylated 3H9 and horseradish peroxidase-labeled streptavidin. If ADAMTS-13 was not captured by 1C4, the conformation of ADAMTS-13 was folded (•, conformation index of < 0.5). If ADAMTS-13 was captured by 1C4, the conformation of ADAMTS-13 was open (○, conformation index of > 0.5). ***P < 0.0001, **P < 0.01, one-way ANOVA. (B) The same plasma samples as in (A) of acute aTTP patients were now preincubated with the anti-CUB1 antibody 17G2 (+ 17G2) (inducing an [additional] open conformation in ADAMTS-13) before addition to the wells coated with 1C4. ***P < 0.0001, paired t-test. (C) The link between the conformation of ADAMTS-13 in matched plasma samples of acute aTTP patients and aTTP patients in remission is represented. ***P < 0.0001, paired t-test.
folded conformation (Fig. 4A; Table S3 ). Here also, the conformation of folded ADAMTS-13 was changed to an open conformation by 17G2 (Fig. S3) . Only one HUS patient (HUS 08) had an open ADAMTS-13 conformation (Fig. 4A) . As ADAMTS-13 levels are decreased during sepsis (Fig. 2) , we also analyzed the ADAMTS-13 conformation in acute sepsis patients [24] . ADAMTS-13 had a folded conformation in all sepsis patients (Fig. 4A ) that changed to an open conformation when 17G2 was added (Fig. S3) .
The open conformation is specific for acute aTTP, as it does not occur in HUS and sepsis.
Discussion
In this study, the anti-spacer domain antibody 1C4, which recognizes a cryptic epitope in ADAMTS-13, was selected. Antibody 1C4 specifically captured open but not folded ADAMTS-13. Using this unique tool, we demonstrated that an open ADAMTS-13 conformation is a hallmark of acute aTTP. ADAMTS-13 is open during the acute phase of aTTP but folded during remission. ADAMTS-13 is also folded in HDs and HUS and sepsis patients. Our data showed that the open ADAMTS-13 conformation is a novel factor that determines an acute aTTP episode.
An open conformation of ADAMTS-13 is a hallmark of acute aTTP
Recently, it was suggested that ADAMTS-13 circulates in a folded conformation through a spacer-CUB interaction, which is disrupted upon binding to its substrate VWF. Alternatively, changes in pH and addition of activating murine anti-ADAMTS-13 antibodies could also induce an open ADAMTS-13 conformation in vitro [5, 21] . With the availability of our 1C4 antibody, we confirm that the majority of ADAMTS-13 in HDs does indeed circulate in a folded conformation.
We next showed that ADAMTS-13 is open during the acute phase of aTTP. This is in line with the presence of altered conformations of self-antigens in other autoimmune disorders, such as APS and HIT [8, 25] . Interestingly, different types of open conformations of ADAMTS-13 seem to exist during acute aTTP. The different conformation indices reflect different affinities for 1C4, and hence different conformations of ADAMTS-13. Remarkably, the altered ADAMTS-13 conformation during an acute aTTP episode is restored during remission in the majority of the patients. This implies that the factor that induced the open conformation of ADAMTS-13 during the acute phase is absent during remission. Now, the factor that modifies the ADAMTS-13 conformation during acute aTTP has to be identified. Triggers such as infection, pregnancy, stress and surgery can induce acute aTTP. Whether common processes in these factors, such as post-translational modifications (deglycosylation and oxidation) and inflammation, are possible candidates for exposing cryptic epitopes in ADAMTS-13 remains to be determined [26] [27] [28] . Alternatively, anti-ADAMTS-13 autoantibodies might also explain the exposure of cryptic epitopes, as these were absent in the majority of the aTTP patients during remission. Insights into how this altered ADAMTS-13 conformation impacts on immune-mediated ADAMTS-13 deficiency will help to further elucidate the pathophysiology of aTTP, and will lead to better treatment and diagnosis of aTTP patients.
Development of acute aTTP: a multifactorial process
ATTP is characterized by a loss of self-tolerance to ADAMTS-13, mainly because of the presence of anti-ADAMTS-13 autoantibodies. The origin of this loss of self-tolerance and why anti-ADAMTS-13 autoantibodies develop are currently not known, although several factors have been described, including genetic factors such as gender, ethnicity, and HLA haplotype [29] [30] [31] , or molecular mimicry, whereby common structural features between the pathogen and the peptides derived from the self-antigen induce an immune response [30, 32] .
Until now, an acute aTTP episode has been characterized by a combination of severe thrombocytopenia, hemolytic anemia, ADAMTS-13 activity of < 10% and the presence of anti-ADAMTS-13 antibodies in most patients (Fig. 5) . With this study, we add an additional important characteristic for an acute aTTP episode, namely an open conformation of ADAMTS-13 (Fig. 5) . Despite the overlap between the major binding site for anti-ADAMTS-13 autoantibodies in the spacer domain and the epitope of antibody 1C4 [12, 33, 34] , an open ADAMTS-13 conformation could still be detected, probably because of the high affinity of 1C4, which allows 1C4 to compete with patient antibodies. Although, in vitro, an open ADAMTS-13 conformation was associated with increased proteolysis of VWF [5] [6] [7] , this does not contradict the presence of both open ADAMTS-13 and ADAMTS-13 activity levels of < 10% in an acute aTTP episode. Indeed, severe deficiency of ADAMTS-13 during an acute aTTP episode is explained by the presence of the anti-ADAMTS-13 autoantibodies, which either inhibit ADAMTS-13 activity or clear the antigen from the circulation.
A combination of the multiple factors stated above (thrombocytopenia, hemolytic anemia, ADAMTS-13 activity of < 10%, the presence of anti-ADAMTS-13 autoantibodies, and an open ADAMTS-13 conformation) is needed to elicit an acute aTTP episode and could explain why patients in remission can have either undetectable ADAMTS-13 activity [35] , anti-ADAMTS-13 antibodies [36, 37] or an open conformation of ADAMTS-13 without disease manifestation. However, it has already been shown that aTTP patients with undetectable ADAMTS-13 activity (< 10%), or anti-ADAMTS-13 autoantibodies during remission have a three-fold higher chance of relapsing [37] . It is hence tempting to speculate that the patients in remission with an open ADAMTS-13 conformation might also be more prone to relapse. Therefore, the 1C4-based ELISA could be used in the diagnosis of aTTP, and might help to predict a relapse during regular patient follow-up.
The presence of open ADAMTS-13 during acute aTTP could contribute in different ways to the pathophysiology of aTTP. In this model, anti-ADAMTS-13 autoantibodies or other factors could induce a conformational change in ADAMTS-13, resulting in the exposure of cryptic epitopes that could lead to an (additional) immune response. Exposure of cryptic epitopes in ADAMTS-13 could then allow binding of anti-spacer autoantibodies, thereby inhibiting ADAMTS-13 function or inducing clearance of the resulting immune complexes.
In conclusion, by using our unique tool, the 1C4-based ELISA, we show here that the ADAMTS-13 conformation in acute aTTP patients is altered as compared with the conformation in HDs and sepsis patients, HUS patients, and TTP patients in remission. We propose that conversion of ADAMTS-13 from a closed to an open conformation is a crucial event during the onset of aTTP. Determining the ADAMTS-13 conformation could help in the diagnosis and prognosis of aTTP. S  T2  T3  T4   T5  T6  T7  T8   CUB2 CUB1   Open ADAMTS-13   M   D   T1 C  S  T2  T3  T4   T5  T6  T7  T8   CUB2 CUB1   < 10% activity   Conformational change of  ADAMTS-13 Presence of anti-ADAMTS-13 autoantibodies Acute aTTP Absent ADAMTS-13 activity Blood parameters Severe thrombocytopenia Hemolytic anemia Fig. 5 . A multifactorial process leads to an acute acquired thrombotic thrombocytopenic purpura (aTTP) episode. Previously, several factors have been attributed to an acute aTTP episode. Factors such as severe thrombocytopenia and hemolytic anemia, ADAMTS-13 activity of < 10% and the presence of anti-ADAMTS-13 autoantibodies are known to be associated with an acute aTTP episode. We have now added an additional factor that is characteristic for an acute aTTP episode, namely an open ADAMTS-13 conformation in which cryptic epitopes are exposed. In the future, other factors may be discovered that also play a role in the multifactorial process that evokes an acute aTTP episode.
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